Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

LY 163892

Known as: LY-163892, LY163892 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1992
1992
In this single-blind study, 579 patients with chronic bronchitis were randomly assigned to receive 400 mg of loracarbef twice… Expand
Is this relevant?
1992
1992
In this single-blind study, 488 patients with acute bronchitis were randomly assigned to receive 400 mg of loracarbef twice daily… Expand
Is this relevant?
1992
1992
A double blind, randomized clinical trial compared loracarbef (LY163892) with penicillin VK. Two hundred thirty-three pediatric… Expand
Is this relevant?
1992
1992
In this double-blind study, 319 patients (133 men, 186 women) with acute bronchitis were randomly assigned to receive 200 mg of… Expand
Is this relevant?
1990
1990
Of six new oral cephalosporins, cefixime and cefpodoxime were the most active (MIC for 90% of isolates tested [MIC90], 16… Expand
  • table 1
Is this relevant?
1988
1988
The in vitro activity of LY163892, a synthetic oral cephalosporin, was compared with those of cefaclor and cefuroxime against 1… Expand
  • table 1
  • table 2
  • table 3
Is this relevant?
1988
1988
LY163892 was found to be similar to cefaclor and slightly superior to cephalexin in antimicrobial activity and spectrum. Bacteria… Expand
Is this relevant?
1988
1988
A new carbacephem analog of cefaclor, LY163892, was examined along with four other cephalosporins for chemical stability and for… Expand
Is this relevant?
1988
1988
LY163892 is a carbacephem antibiotic for oral administration with an antibacterial spectrum similar to that of cefaclor and… Expand
Is this relevant?
1988
1988
LY163892 is a new orally absorbed carbacephem. It inhibited Streptococcus pyogenes and Str. pneumoniae at less than or equal to 1… Expand
Is this relevant?